Hoth Therapeutics Inc Stock Price, News & Analysis

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a 1-for-25 reverse stock split effective at 12:01 a.m. Eastern Time on October 26, 2022. This decision aims to comply with the Nasdaq’s $1.00 minimum bid price requirement for continued listing. Post-split, approximately 1,288,468 shares will be outstanding, and authorized shares will adjust to 3,000,000. The company will continue trading under the symbol HOTH. However, there is no guarantee this split will ensure compliance with Nasdaq standards.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a partnership with Altasciences to develop the HT-TBI drug formulation aimed at treating secondary brain injuries from ischemic stroke and traumatic brain injury (TBI). This ready-to-use drug-device combination will be designed for use in non-healthcare settings by patients, caregivers, and emergency responders. The development will support a future Investigational New Drug (IND) application for clinical trials. The global acute ischemic stroke market is projected to reach $2.7 billion by 2029.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced promising results for its HT-004 treatment, which significantly reduced lung inflammation in an asthma mouse model after an ovalalbumin challenge. This innovative therapy utilizes a chemically-stable antisense oligonucleotide to inhibit IgE receptor function, leading to reduced mast cell activation. Collaborating with North Carolina State University, Hoth aims to explore HT-004's potential in larger animal models, further developing this candidate for asthma and allergic disorders. Hoth is also seeking patent protection for this intellectual property.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced its presentation at the Sidoti Investor Conference on August 17-18, 2022. The company focuses on developing innovative biopharmaceutical treatments aimed at improving patient quality of life. Hoth is dedicated to early-stage pharmaceutical research and collaborates with scientists and clinicians to explore impactful therapeutics. For more details on the conference, interested parties can visit the Sidoti website.

Hoth Therapeutics (NASDAQ: HOTH) announced promising results from a study of HT-ALZ, a treatment for Alzheimer's disease (AD), demonstrating significant cognitive improvements in behavioral tests after chronic dosing in a mouse model. Conducted in collaboration with Washington University, the study showed that after more than five weeks of treatment, HT-ALZ-treated mice exhibited notable enhancements compared to vehicle-treated controls. Future research will further explore the treatment's effects, including memory and anxiety, providing optimism for its potential in AD therapy.

Hoth Therapeutics, Inc. (Nasdaq: HOTH) received a 180-day extension from Nasdaq to comply with the $1.00 minimum bid price requirement, giving the company until December 26, 2022, to regain compliance. This decision follows an earlier notification from Nasdaq regarding Hoth's non-compliance based on its stock performance over the previous 30 days. If the company achieves the bid price requirement for 10 consecutive business days during this period, Nasdaq will confirm compliance. Failure to do so may lead to potential delisting, though the company can appeal such a decision.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that it has received approval from the Bellberry Human Research Ethics Committee in Australia to proceed with the next phase of its BioLexa trial for Atopic Dermatitis patients. This approval marks a significant milestone in Hoth's clinical trial journey. BioLexa is a patented antimicrobial topical formulation designed to prevent Staphylococcal biofilm formation, which is critical for treating chronic infections that can lead to antibiotic resistance. The company aims to leverage this opportunity to enhance patient quality of life through innovative therapies.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced that its Annual Meeting of Shareholders, originally scheduled for June 15, 2022, has been adjourned until June 23, 2022, at 12:00 p.m. ET. This decision aims to allow additional time for proxy solicitation and to achieve a quorum for voting. The meeting will be conducted virtually. Shareholders of record as of April 25, 2022, are encouraged to vote their shares by 11:59 p.m. ET on June 22, 2022. No changes to the proposals for the meeting have been made.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced an extension of its Sponsored Research Agreement with Washington University in St. Louis to further investigate HT-ALZ, a potential treatment for Alzheimer's disease. The ongoing research aims to establish a human equivalent dose for HT-ALZ, based on previous studies showing its ability to reduce amyloid β (Aβ) levels in mouse models. The study is led by Dr. Carla Yuede and Dr. John Cirrito, focusing on the effects of chronic administration on cognitive outcomes in Alzheimer’s models.